Key statistics
On Friday, Aquestive Therapeutics Inc (AQST:NMQ) closed at 5.46, -12.36% below its 52-week high of 6.23, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.10 |
---|---|
High | 5.51 |
Low | 4.98 |
Bid | 5.26 |
Offer | 5.45 |
Previous close | 5.08 |
Average volume | 1.81m |
---|---|
Shares outstanding | 91.18m |
Free float | 86.61m |
P/E (TTM) | -- |
Market cap | 497.83m USD |
EPS (TTM) | -0.3565 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
- Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
- Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
- Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
More ▼